Physician profile
Vincence F Dillon
NPI 1437195534
$1,784.90
in general payments reported to CMS, 2019-2025
19 companies · $842 in 2025
The $842 reported for 2025 was more than what 81% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2022: $54.10 · 2023: $238 · 2024: $545 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $238.29 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $198.66 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.82 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $134.82 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $130.93 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $124.16 | 2023-2025 | Auvelity, Sunosi |
| Neos Therapeutics, Lp | $102.76 | 2019-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $87.62 | 2023-2025 | Dyanavel Xr |
| Alkermes, INC. | $87.46 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $77.44 | 2024-2025 | Fanapt |
| Lundbeck LLC | $77.24 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $76.06 | 2019-2024 | Jornay Pm |
| Almatica Pharma LLC | $70.35 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $59.24 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $44.90 | 2025 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $39.93 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.91 | 2024 | Trintellix |
| Neuronetics, INC. | $18.54 | 2019 | |
| Abbvie INC. | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincence Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.